New products push Dainippon Sumitomo to growth
This article was originally published in Scrip
Executive Summary
The launch of two new drugs helped Dainippon Sumitomo Pharma(DSP) ride out the general April price cut and falling sales of its main product in Japan in the first half to September 30th, when the firm's total consolidated net sales rose by 4% to ¥134.4 billion ($1.36 billion).